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Priorities for tuberculosis research: a systematic review
Jamie Rylance, Madhukar Pai, Christian Lienhardt, Paul Garner
Reliable and relevant research can help to improve tuberculosis control worldwide. In recent years, various 
organisations have assessed research needs and proposed priorities for tuberculosis. We summarise existing priority 
statements and assess the rigour of the methods used to generate them. We found 33 documents that speciﬁ cally 
outline priorities in tuberculosis research. The top priority areas were drug development (28 articles), diagnosis and 
diagnostic tests (27), epidemiology (20), health services research (16), basic research (13), and vaccine development 
and use (13). The most focused questions were on the treatment and prevention of multidrug-resistant tuberculosis 
in people co-infected with HIV. Methods used to identify these priorities were varied. Improvements can be made to 
ensure the process is more rigorous and transparent, and to use existing research or systematic reviews more often. 
WHO, Stop TB Partnership, and other organisations could adopt an incremental process of priority development, 
building on the existing knowledge base. 
Introduction
There are more than 9 million new cases of tuberculosis 
every year worldwide, and incidence is declining at a rate 
of less than 1% per year.1 Nearly 2 million people die from 
tuberculosis every year, and the costs and social 
consequences of this disease are vast. This worldwide 
burden of tuberculosis has stimulated much interest in 
research for new approaches to the management of this 
disease. Various organisations, individuals, and networks 
have tried to identify priorities to help guide and to 
stimulate appropriate funding. The explicit  and rational 
setting of research priorities is integral to the research 
process: for allocation of resources into areas of strategic 
importance, to catalyse debate, and to strengthen the role 
of stakeholders in establishing the research agenda.2 
Ultimately, this strategy should help to improve the 
allocation and monitoring of funding3 and the progress 
towards targets in tuberculosis control.4
Several approaches to facilitate setting of priorities for 
research have been described, which aim to increase 
transparency, objectivity, acceptability, and validity of the 
results. To  judge the merits of competing priorities, 
agreed criteria are needed. Information on expected cost, 
existing capacity, eﬀ ect of the research, and eﬀ ect on the 
population that is expected to beneﬁ t is also needed. 
Several techniques have been used, including the Delphi 
method (iterative broad consultation with a range of 
experts), trend analysis and modelling (forward 
extrapolation of historical data on the eﬀ ect of certain 
research), scenario discussion (assessment of current 
priorities on the basis of a structured discussion of the 
potential outcomes), and matrix approaches (that use 
information on cost-eﬀ ectiveness and other quantiﬁ able 
data on the potential eﬀ ect to direct the use of restricted 
resources).5
We aimed to systematically summarise priority topics 
for tuberculosis research from available publications and 
to describe how priorities were identiﬁ ed. This systematic 
review will help to inform new initiatives for identifying 
and setting research priorities, such as for the recently 
established Research Movement of the Stop TB 
Partnership, which  aims to increase the scope, scale, and 
speed of tuberculosis research and to ensure that research 
priorities are identiﬁ ed and properly funded.
Methods 
Search strategy and selection criteria
We searched PubMed for studies published from 1998 
to June 5, 2010, with the terms: (1) tuberculosis[tiab] 
OR mycobacter*[ti] OR (tuberculosis/epidemiology/pre-
vention and control); (2) (research[ti] AND agend*[ti]) OR 
(research[ti] AND priorit*[ti]) OR (research[ti] AND 
need[ti]) OR (resource allocation/organisation and 
administration) OR (health services needs and demand) 
OR (research support); and (3) #1 AND #2. We also 
included publications cited in the documents when 
relevant. We contacted representatives of Stop TB 
Partnership and WHO to identify potentially relevant 
documents, especially for articles that might not have 
been indexed in PubMed; we also accessed information 
from the TB Research Movement collection. We did not 
use any restrictions for the language of the published 
studies. We excluded primary research and individual 
systematic reviews of speciﬁ c interventions or topics. We 
also excluded papers that reprinted research priorities 
identiﬁ ed in previous studies. 
Data abstraction and synthesis
The search results were screened by two authors (JR and 
PG) independently; documents were included if there 
was reference to research prioritisation or research topics 
and speciﬁ c mention of tuberculosis in the abstract. 
Discordant decisions were resolved by consensus.
Articles were classiﬁ ed into two types: consensus 
statements from a convened group or expert panel or 
reviews or commentaries on the state of tuberculosis 
research that mentioned priorities or agendas for future 
work. We noted the aﬃ  liation of authors and investigated 
the methods used to reach conclusions. We identiﬁ ed the 
most frequently recurring questions and areas of interest. 
Details were extracted and coded for each article and for 
each question highlighted. Data were coded according to 
a piloted list of summary categories to enable analysis. 
Data extraction was done by JR and PG, and results were 
For more on the TB Research 
Movement Collection see 
http://www.stoptb.org/
resources/
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directly compared for veriﬁ cation and entered into 
Microsoft Access.
Results 
1004 articles were screened and 51 were shortlisted for full-
text review (ﬁ gure). 18 papers were excluded (webappendix); 
33 were included.6–38 12 of 33 articles were consensus 
statements;6,8,13,20–22,27–32 11 of which were published in the 
past 5 years. WHO published three overviews of research 
priorities derived from expert consensus meetings held in 
2005 with a wide range of questions. One focused on 
tuberculosis and HIV,21 one assessed tuberculosis more 
broadly,22 and the 2009 tuberculosis treatment guidelines28 
contributed further suggestions for research arising from 
a series of system atic reviews. Another multidisciplinary 
international working group (the International Standards 
for TB Care steering committee) produced standards for 
tuberculosis care directed at healthcare providers that are 
applicable worldwide. As part of this process, the authors 
derived a set of research priorities covering clinical case 
management, treatment and monitoring, and operational 
research.20
Three consensus statements highlighted and proposed 
research priorities for multidrug-resistant (MDR) 
tuberculosis. A consensus statement on MDR 
tuberculosis was published by the Stop TB Partnership’s 
working group on MDR tuberculosis.13 The research 
subgroup of the working group on MDR tuberculosis 
produced a document in which they investigated the 
scale-up of programmatic management of MDR 
tuberculosis and related research priorities.8 A 
collaboration of European scientiﬁ c academies made 
recommendations for work on MDR tuberculosis 
funded by the European Union.29 A further three 
consensus statements came from funding agencies, one 
in the USA and two from Europe. The US statement, 
from the National Institute of Allergy and Infectious 
Disease, described current and future plans for research 
on MDR tuberculosis funded through the National 
Institutes of Health.27 A group of authors of European 
Commission-funded projects produced a prioritisation 
programme for research in neglected infectious 
diseases, which made recommendations for tuberculosis 
research,6 and another article described the current and 
European Commission-funded tuberculosis research 
portfolio with recommendations for future direction of 
ﬁ nances.30 The European Commission also supported 
another workshop on vaccine adjuvant research 
priorities.31 Lastly, a broadly drawn expert group 
published a paper on how to investigate the joint burden 
of diabetes mellitus and tuberculosis.32
The other 21 articles were reviews and commentaries; 
six focused on tuberculosis in children,9,12,14,25,26,33 whereas 
the rest were not age speciﬁ c. Three articles were related 
speciﬁ cally to HIV,7,25,34 and two to MDR tuberculosis.15,35 
Seven articles summarised the broad state and priorities 
of tuberculosis research. Speciﬁ c topics addressed were 
drug treatments,11,14,26,37 diagnostics,19,23,25,36 preventive 
therapy,7 health service limitations,16 funding,17 and design 
of clinical trials for tuberculosis drugs.35
Table 1 provides a summary of the methods used to 
develop the research priorities in the studies. 
13 articles were derived from the questions from an 
expert meeting. Of these, three stated that expert 
advice was sought beyond the panel. Two of the 
consensus groups reported inclusion of representation 
of patients or communities. One article reported a 
systematic review of relevant evidence with a speciﬁ c 
search strategy.9 Two groups seemed to collate data from 
primary research articles comprehensively, although 
they did not state their strategy.7,36 Most articles (27 of 33) 
presented selected details from primary literature in 
conventional narrative review format, and gave no details 
of search terms, indexing databases, or inclusion and 
exclusion criteria.6,7,10–13,15–27,29–35,38  
Research areas highlighted in the studies were 
identiﬁ ed with various methods. Four of the 12 consensus 
Consensus statements 
(12 articles); n (%)
Review and commentary 
articles (21 articles); n (%)
Total 
(33 articles); 
n (%)
Systematic reviews used 3 (25) 6 (29) 9 (27)
Search strategy speciﬁ ed 1 (8) 3 (14) 4 (12)
Systematic synthesis of data* 1 (8) 3 (14) 4 (12)
External advice sought beyond the 
panel of experts from meeting†
5 (42) 4 (19) 9 (27)
Representatives for patients 
involved
2 (17) 0 (0) 2 (6)
Method of question identiﬁ cation 
described
8 (67) 5 (24) 13 (39)
Method of prioritisation described 4 (33) 1 (5) 5 (15)
*Synthesis refers to a systematic analysis of primary research. †External refers to  external advice to the authors or 
consensus panel members.
Table 1: Summary of methods used to develop research priorities for tuberculosis
Figure: Flow chart of study selection
1004 publications screened and 
            assessed for eligibility
      953 publications excluded due to lack of relevance 
               (ie, abstract made no speciﬁc reference to 
               tuberculosis or research areas)
      51 potentially relevant articles 
            retrieved for full review
         18 articles excluded due to content (ie, did not 
               identify any speciﬁc research priorities 
               or questions)
      33 articles assessed
            12 derived from expert groups
            21 commentary or review articles
See Online for webappendix
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statements used the opinion of expert subgroups or were 
derived from group discussion.13,21,22,30 In three consensus 
papers, systematic reviews were commissioned to inform 
an expert group,20,28,32 and the Stop TB Partnership 
working group on MDR tuberculosis used established 
WHO guidelines to critically appraise existing 
publications for gaps in knowledge.8 The other four 
consensus articles gave no indication of how research 
areas were identiﬁ ed.6,27,29,31 Commentary articles identiﬁ ed 
knowledge gaps by systematic review in three cases,7,9,14 
and three articles discussed selected results of existing 
systematic reviews.19,25,36 Two reported on  brainstorming 
exercises.17,18 The rest of the commentary papers (13 of 21) 
did not specify the methods used and did not make use 
of systematic reviews.
Four of the consensus articles described some methods 
for ranking the priorities that they identiﬁ ed.8,13,17,27 Two 
used meetings of experts subdivided into ad-hoc 
committees by research subject area; in one, the number 
of questions was limited to ﬁ ve;13 and in the other, 
participants ranked the questions they had generated by 
perceived importance, and reﬁ ned the list by wider expert 
consultation.8 One article reported a seven-step analysis 
process that was used to compare research needs for the 
portfolio of diseases in the WHO Special Programme for 
Research and Training in Tropical Diseases.17 This paper 
used an analysis of current and projected burden of 
disease, current control limitations, research gaps, and 
opportunities. No further details were available from the 
article on how these opportunities were identiﬁ ed. One 
article used internal and external advisers to estimate the 
relative potential of research areas to “contribute 
substantially to a global public health response”,27 
although it did not show which criteria were used to 
assess these relative potentials.
The number and type of research questions varied 
widely across the articles. Some articles provided many 
questions (ten suggested more than 20, of which only one 
group had attempted relative prioritisation)—277 question 
areas were identiﬁ ed. Research was speciﬁ cally suggested 
for HIV-infected persons (63 questions), MDR 
tuberculosis (49), malnutrition (nine), and diabetes 
(seven). The mean number of research questions per 
article was 17 (range 1–78). Consensus statements had 
more questions on average (mean of 21 questions) than 
did reviews and opinion pieces (mean of 15 questions).
Research priorities were expressed diﬀ erently across 
articles. Nine articles9,10,12,18,20,22,24,30,33 took into account the 
wide remit of tuberculosis research in general, of which 
three20–22 used expert subgroups within each area of 
interest. Most other articles were more focused, including 
ﬁ ve articles on MDR tuberculosis and drug develop-
ment,8,13,15,27,29 four on HIV co-infection,7,21,25,34 and two on 
laboratory diagnostics and vaccination.19,31 Single articles 
focused individually on health system research,16 
tuberculosis treatment guidelines,28 tuberculosis and 
diabetes mellitus,32 and design factors in drug trials.35
Most articles identiﬁ ed treatment with drugs, drug 
development, and diagnostics as areas of research priority 
(table 2). 17 articles identiﬁ ed questions relating 
speciﬁ cally to children. With regard to HIV-infected 
populations, the most commonly cited questions related 
to antituberculous drug treatment regimens (16 articles), 
diagnosis (15), and epidemiology (7). The pattern for 
MDR tuberculosis was similar, with drug treatment (ten), 
n
Drug development and use (7 or more articles) 28
Studies for eﬀ ectiveness of chemoprophylaxis* 9
Optimum duration of drug treatment: new and old 
regimens*
9
Development of new antituberculous drugs 7
Pharmacokinetics of ﬁ rst-line drugs* 7
Pharmacokinetics of second-line drugs* 7
Drug interaction studies (with concomitant 
antiretroviral use)
7
Diagnosis and diagnostic tests (8 or more articles) 27
New diagnostic tests for active tuberculosis* 14
New methods for drug sensitivity testing 11
Evaluation of diagnostic pathway for the diagnosis of 
active tuberculosis* 
8
Biomarkers of successful treatment (for clinical or 
future trial use)
8
Epidemiology and public health (5 or more articles) 20
Accurate measurement of the global burden of 
tuberculosis* 
8
Identiﬁ cation of the role of social factors within 
communities on the risk of infection or transmission
5
Eﬀ ect of treatment literacy programmes on adherence 
and burden of disease
5
Health services research (4 or more articles) 16
Investigation of the causes of diagnostic delay 4
Modelling tuberculosis-associated costs or health 
service requirements
4
Role of patients in case ﬁ nding 4
Best model for integration of tuberculosis and HIV 
services
4
Training requirements for staﬀ  providing tuberculosis 
care
4
Basic science research (3 or more articles) 13
Identiﬁ cation of host correlates of protection against 
tuberculosis
4
Understanding latent infection and latency 4
Understanding genetic and phenotypic markers of 
tuberculosis resistance
4
Development of an animal model that can help to 
predict treatment duration
4
Vaccine development and use (2 or more articles) 13
Development and trials of new tuberculosis vaccine* 8
*Questions most commonly in reference to children (four articles or more).
Table 2: Number of studies identifying priority topics for tuberculosis 
research
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diagnosis (11), and epidemiology (ten) highlighted. The 
panel lists the most common research areas highlighted 
for HIV co-infection and MDR tuberculosis. Systematic 
reviews were used more often for papers that had 
questions related to drug development, diagnostics, and 
epidemiology (ﬁ ve of nine articles that used these 
methods identiﬁ ed questions in these areas). By contrast, 
systematic reviews were only done in two articles that 
identiﬁ ed questions on basic science and vaccines.
14 of the 33 articles were by authors who originated 
from academic institutions, ten were by members of 
WHO or Stop TB Partnership (often jointly), and nine 
were by authors from non-governmental organisations 
(ﬁ ve), governmental or funding agencies (three), and a 
science advisory body (one). 223 individuals were named 
as authors. Authors were most commonly aﬃ  liated with 
academic institutions, followed by WHO, and government 
staﬀ  (table 3). Representatives of funding organisations 
did not commonly co-author the articles (two). Patients 
were directly represented in two cases, both for papers on 
treatment guidelines. 40 individuals were listed as 
authors on more than one of the included articles; 
12 contributed to more than two; and ﬁ ve contributed to 
more than three. Authorship of more than one article 
was most common for authors from universities (41%) 
and those aﬃ  liated with WHO and Stop TB Partnership 
(21%). The mean number of authors per article was nine 
(range 1–28); for consensus statements, the mean 
number of authors was 15 (range 2–28), and for reviews 
the mean was ﬁ ve (range 1–14). 
20 of the articles included a statement of conﬂ icts of 
interest. In three articles, the author’s aﬃ  liation indicated 
that publication would promote an organisation’s 
interests, but no conﬂ ict of interest statement was 
speciﬁ cally published.10,23,24 There is, however, some 
evidence of a recent change in practice—in articles 
published between 1998 and 2005, one of six articles 
included a statement; from 2006 to 2010, 19 of 27 did so.
Discussion
We identiﬁ ed 33 research agendas for tuberculosis 
published between 1998 and 2010. Two clear research 
priorities emerged from this systematic review: the 
development and testing of both new drugs and treatment 
regimens, and new diagnostic tests for tuberculosis. 
These areas also dominated when focusing on the 
research needs in speciﬁ c populations such as patients 
co-infected with HIV or patients with MDR tuberculosis, 
who are particularly aﬀ ected by the limitations of current 
drugs and diagnostics. This ﬁ nding is indicative of the 
ineﬃ  ciencies of the currently used sputum-smear-based 
diagnosis in many cases and of the observation that 
short-course chemotherapy, despite 95% eﬃ  cacy in 
clinical trials, has not substantially contributed to 
decreasing the transmission of tuberculosis in areas with 
high HIV burden nor been eﬀ ective for patients with 
drug-resistant tuberculosis.39,40
The use of epidemiology in these studies as a means to 
better understand the factors involved in the worldwide 
burden of disease and to assess the eﬀ ect of case-ﬁ nding 
was notable. The frequent inclusion of epidemiology 
emphasises the importance of doing studies at the 
population level to better target control interventions and 
possibly highlights a perception that accurately 
documenting the burden of disease might help to 
advocate allocation of resources for research. Epidemio-
logical and impact-assessment studies are also necessary 
for monitoring and evaluation and to check if the Stop 
TB Partnership strategy is actually eﬀ ective in controlling 
tuberculosis.41 Research into health services was also 
identiﬁ ed to be a common priority; this emphasis on 
operational research might be indicative of the need to 
optimise the availability and cost-eﬀ ectiveness of 
techniques for improved tuberculosis control at the 
programme level in resource-limited settings. 
Panel: Common research areas about HIV co-infection and MDR tuberculosis 
HIV
• Optimum tuberculosis treatment using existing drugs for HIV co-infection
• Optimum duration of therapy (tuberculosis ﬁ rst-line drugs)
• Role of intensive case-ﬁ nding in communities with high prevalence of HIV
• Studies of eﬀ ectiveness of isoniazid as a preventive therapy 
• Pharmacokinetic interaction studies
• Optimum role of co-trimoxazole in HIV co-infection
• Best integration of tuberculosis and HIV services 
• Optimum time for initiation of antiretrovirals in tuberculosis and HIV co-infection
MDR tuberculosis
• New diagnostics for drug sensitivity testing
• Selection algorithms for drug sensitivity testing in existing programmes
• Use of standardised regimens for MDR tuberculosis treatment
• Eﬃ  cacy studies of second-line drugs
• Safety studies of second-line drugs
• Pharmacokinetic and pharmacodynamic studies of second-line drugs
• Chemoprophylactic regimens for those in contact with MDR tuberculosis-aﬀ ected 
individuals 
• Burden of MDR tuberculosis 
Research areas were identiﬁ ed in more than three articles. MDR=multi-drug resistant.
n (%)
Academic aﬃ  liation 92 (41)
WHO or TDR or Stop TB Partnership* 46 (21)
Governmental organisation 40 (18)
Other† 45 (20)
*Author numbers from these organisations are combined. †Authors from 
non-governmental organisations (18), national control programmes (nine), 
private sector workers (four), professional medical organisations (four), clinicians 
(four), funding organisations (two), medical students (one), activists for patients 
(two), or unknown (one). TDR=Special Programme for Research and Training in 
Tropical Diseases.
Table 3: Author aﬃ  liations (n=223)
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Investigation of basic science questions aimed at 
contributing to the research and development pipeline 
was less commonly identiﬁ ed as a priority. Fundamental 
research on prominent ﬁ elds, such as the biology of 
Mycobacterium tuberculosis, the host-pathogen inter-
actions, and the latency and persistence patterns, is 
essential for the development of new diagnostic tests and 
drugs.24 Similarly, this research should support work on 
vaccine development, which was also relatively less 
prioritised than are other research areas.
According to a Treatment Action Group report on 
tuberculosis research and development funding, 
investments in tuberculosis research and development in 
2007 were mostly in drug development (US$170 million, 
35%), basic science ($121 million, 25%), and vaccine 
development ($71 million, 15%), compared with diagnostics 
($41 million, 9%) and operational research ($36 million, 
8%).3 One potential explanation for this apparent diﬀ erence 
in allocation of funds is that, in the research topics reviewed 
here, the relative importance of drugs and diagnosis 
compared with basic and operation research is probably 
indicative of the diﬃ  culty of establishing clear research 
agendas in these areas rather than an absence of perception 
of priority. Basic research is mostly driven by curiosity and 
might therefore not beneﬁ t from ﬁ tting into speciﬁ c topic 
areas that could be perceived as restrictive or limited. 
Because operational research is closely linked to 
programme implementation, this research falls 
comparatively short of funding and seems to be more 
diﬃ  cult to prioritise in deﬁ nite research agendas. 
Use of systematic reviews to help establish tuberculosis 
research priorities is uncommon. Systematic reviews 
might not always be necessary; for example, because 
research in that area is recent. However, the use of 
systematic review has received growing attention in 
recent years and is increasingly being recognised as an 
important approach to the assessment of research42 by 
providing an inventory on what is known.
Although there are formal methods for prioritising 
research, few of the consensus groups used them. Group 
discussion methods tended to provide large com-
prehensive lists of questions without prioritisation, such 
as the report by WHO and the Special Programme for 
Research and Training in Tropical Diseases report on 
tuberculosis.22 Listing of questions might help in reaching 
a consensus in a large diverse group, but is less helpful 
in targeting strategic areas or in deciding on research 
funding allocation. This approach might be useful, 
however, for raising awareness and for funding in speciﬁ c 
research domains. The consensus statement on short-
course directly observed treatment for MDR tuberculosis, 
by contrast, was able to distil the list of identiﬁ ed topics 
into focused, prioritised research questions.13 Such an 
approach might be more useful in guiding scientists and 
funding agencies.
The pool of academics and specialists involved in these 
articles was relatively small and many authors contributed 
to more than one document. There was little 
representation for patients. Although we do not know 
what eﬀ ect they would have on priorities, involvement of 
patients is likely to help focus research on outcomes that 
interest those with disease. Collaboration with patients is 
valuable to researchers, clinicians, and funding 
organisations, and is well documented in other areas.43 
Additionally, conﬂ icts of interest were not stated in many 
articles. Disclosure of conﬂ icts of interest should be 
universally implemented, as has recently been adopted 
for expert meetings at WHO.
Although care was taken to include a comprehensive 
search of papers, some notable documents might have 
been overlooked. We studied the methods used to identify 
and recommend research priorities. However, this study 
does not answer an important question for researchers: 
which of the research questions is supported by high-
quality evidence? We expect that by improving 
prioritisation methods, this question could be answered.
To identify key research questions within speciﬁ c areas, 
various people are involved to make decisions about need 
and scientiﬁ c opportunities. This process needs a thorough 
understanding of existing work and a critical analysis of 
existing data through systematic review where appropriate. 
We believe that transparent and speciﬁ c processes are 
important in setting research priorities. Establishing these 
priorities would be enhanced by a structured synthesis of 
existing knowledge, such as that advocated by the Grading 
of Recommendations Assessment, Development and 
Evaluation (GRADE)44 approach. 
Consensus panels understandably tend to favour 
discussion and critical analysis to reach agreement, but 
generally fail to suggest priorities. Formal methods to 
assess the relative merit of priority areas should be more 
widely adopted. This assessment would involve 
establishing clear criteria by which to judge the 
importance of the research questions, such as: the 
potential for progress, the public health need, and the 
potential eﬀ ect on public health.45 Such an approach was 
adopted for research in childhood diseases.46 Criteria for 
establishing research priorities were the following: 
likelihood that the research question would be answerable 
in an ethical way; likelihood that the resulting intervention 
would be eﬀ ective in reducing disease burden; 
deliverability, aﬀ ordability, and sustainability of the 
resulting intervention; maximum potential of the 
intervention to reduce disease burden; and eﬀ ect of 
disease burden reduction on equity in the population. In 
some approaches, a system of voting enables large groups 
of panel members to reach a consensus agreement. This 
system depends on participants being adequately 
informed of the existing knowledge base, such as by 
systematic review. Additionally, panels need to engage 
representatives of patients and have transparent systems 
for expressing potential conﬂ icts of interest. Journals 
should also be consistent in requiring statements about 
potential conﬂ icts of interest. 
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The identiﬁ ed research topics indicate the central role 
of WHO and the Stop TB Partnership in establishing 
guidelines and advocating for better control of 
tuberculosis worldwide. These organisations have 
recently jointly launched the TB Research Movement, 
which will engage many tuberculosis researchers in a 
collaborative strategic eﬀ ort to increase the scope, scale, 
and speed of research to accelerate progress in worldwide 
control of tuberculosis.
The research areas frequently identiﬁ ed and 
summarised here should help to provide a platform for 
explicit development of a transparent and widely approved 
system for the establishment of priorities for tuberculosis 
research, using speciﬁ c criteria and systematic reviews 
combined with expert opinion. Such an approach would 
identify knowledge gaps, inform funding organisations’ 
decisions, and ensure that research is harmonised and 
eﬀ ective. All these steps are crucial to improving 
worldwide control of tuberculosis.
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